



Alameda County Health Advisory: Outpatient Therapies for the Treatment and Prevention of COVID-19 in High-Risk Patients (revisions in red) August 10, 2022

RECENT UPDATES:

- [What's New | COVID-19 Treatment Guidelines \(nih.gov\)](#) (8.8.22)
- [Evusheld](#): Recent major changes, warnings, dosing (June 2022). See also [ACPHD Health Alert](#) (7.21.22).
- [Remdesivir](#): Fully approved for treatment of adults/children for in- and outpatients
- [Paxlovid](#): EUA now allows limited prescribing by Pharmacists
- [Federal Response to COVID-19: Therapeutics Clinical Implementation Guide, Outpatient Administration Guide for Healthcare Providers \(hhs.gov\)](#) (7.18.22)
- CDPH COVID-19 [Test-to-Treat-Playbook.pdf \(ca.gov\)](#) (June 2022) **Note**: A recommendation is included to prescribe therapeutics “to all individuals age 50+ and to populations who face structural barriers to health that have contributed to disproportionate rates of hospitalization and death from COVID-19.” (pg. 6)
- Federal [Test to Treat locator website](#)
- [COVID-19 Therapeutics Locator \(arcgis.com\)](#)

PURPOSE

The purpose of this Health Advisory is to **update** clinicians in Alameda County about the availability of **outpatient therapies for high-risk patients** with 1) mild to moderate COVID-19 illness who are not yet hospitalized; or 2) ongoing risk of exposure to COVID-19. When resources are limited, therapy should be prioritized for patients who are at the highest risk of progressing to severe COVID-19, as described in the NIH Panel’s [interim statement](#). **Currently, it is possible to offer available therapies to all eligible patients.**

TREATMENTS

The Panel’s current COVID outpatient treatment recommendations found in [What's New | COVID-19 Treatment Guidelines \(nih.gov\)](#) are as follows:

Preferred (listed in order of preference):

- [Paxlovid](#)[™] (nirmatrelvir 300 mg plus ritonavir 100 mg) orally twice daily for 5 days
- [Remdesivir](#) IV daily for 3 days

Alternative therapies (for use if none of the preferred therapies are available, feasible to deliver, or clinically appropriate, listed in alphabetical order):

- [Bebtelovimab](#) 175 mg, administered as a single intravenous (IV) infusion
- Lagevrio[™] ([Molnupiravir](#)) 800 mg orally twice daily for 5 days

See also [CDPH Treatment Q & A for Providers](#) and CDPH [Distribution and Ordering](#) on the [CDPH COVID-19 Treatment webpage](#). Register [here](#) for biweekly CDPH webinars for therapeutics providers.



PRE-EXPOSURE PROPHYLAXIS

Evusheld is a combination monoclonal antibody that can only be used in high-risk patients who:

- Do NOT have COVID-19 and have NOT had a recent exposure; AND
 - Have **moderate to severe immunocompromise** due to a medical condition or receipt of immunosuppressive medications or treatments, and may not mount an adequate immune response to COVID-19 vaccination, **OR**
 - **Cannot be vaccinated due to a history of a severe adverse reaction** to a COVID-19 vaccine(s) and/or vaccine component(s).
- **For individuals with a history of severe hypersensitivity reaction to a COVID-19 vaccine, consider consultation with an allergist-immunologist prior to EVUSHELD administration.**
- While the Evusheld fact sheet does not recommend for or against COVID-19 testing prior to administration, a clinical assessment would be appropriate. If there is any concern for COVID-19 infection due to symptoms or exposure, testing should be pursued.
- **The FDA has authorized a change in dosing of Evusheld. Consider repeat dosing every six months if patients need ongoing protection.**
- **New helpline and ordering pathway for Evusheld**

CURRENT AVAILABILITY OF THERAPEUTICS

Two therapeutic locator websites are listed below to identify sources of therapeutics and “test to treat” sites:

- <https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>
- <https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/>

State pharmacy waiver information for Emergency Departments: [Prescriber Dispensing of COVID-19 Oral Therapeutic Medication to Emergency Room Patient](#)

RECOMMENDATIONS FOR CLINICIANS PRESCRIBING MONOCLONAL ANTIBODIES (and possibly Remdesivir) FOR TREATMENT

ACPHD recommends that clinicians with patients who meet the inclusion criteria for the use of outpatient MAB therapy **or Remdesivir** contact the following entities, or other participating medical systems, for information on treatment availability. *Treatment should be coordinated in advance of sending a patient for therapy.*

- a. Outpatients:
 - **Physician referral** through the patient’s health plan
 - **Total Infusion:** <https://totalinfusion.com/make-a-referral/> (*Monoclonal Antibodies only*)
- b. **LTCF Residents:** Specialty Pharmacy associated with an LTCF

If timely appointments in Alameda County are not available for your patients, you can contact the hospitals below:

- a. **Stanford Medical Center, Palo Alto:** Contact DL-SHC-Pharmacy-COVID@stanfordhealthcare.org or (650) 391-8503. [COVID-19 Monoclonal Antibody Therapies - Patients | Stanford Health Care](#)
- b. **UCSF:** [UCSF External Self or Provider Referral for COVID-19 Monoclonal Antibody Outpatient Treatment \(PDF\)](#)

For questions about treatment with COVID-19 outpatient therapeutic products, please contact Arnie Spanjers, MD, at arnie.spanjers@acgov.org